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Anti-inflammatory effects of 
indirubin derivatives on influenza 
A virus-infected human pulmonary 
microvascular endothelial cells
Hoi-Hin Kwok1,2,*, Po-Ying Poon1,2,*, Siu-Ping Fok1,2, Patrick Ying-Kit Yue1,2, Nai-Ki Mak2, 
Michael Chi-Wai Chan3, Joseph Sriyal Malik Peiris3 & Ricky Ngok-Shun Wong1,2
Influenza A virus (IAV) poses global threats to human health. Acute respiratory distress syndrome and 
multi-organ dysfunction are major complications in patients with severe influenza infection. This may 
be explained by the recent studies which highlighted the role of the pulmonary endothelium as the 
center of innate immune cells recruitment and excessive pro-inflammatory cytokines production. In this 
report, we examined the potential immunomodulatory effects of two indirubin derivatives, indirubin-
3′-(2,3-dihydroxypropyl)-oximether (E804) and indirubin-3′-oxime (E231), on IAV (H9N2) infected-
human pulmonary microvascular endothelial cells (HPMECs). Infection of H9N2 on HPMECs induced a 
high level of chemokines and cytokines production including IP-10, RANTES, IL-6, IFN-β and IFN-γ1. 
Post-treatment of E804 or E231 could significantly suppress the production of these cytokines. H9N2 
infection rapidly triggered the activation of innate immunity through phosphorylation of signaling 
molecules including mitogen-activated protein kinases (MAPKs) and signal transducer and activator 
of transcription (STAT) proteins. Using specific inhibitors or small-interfering RNA, we confirmed that 
indirubin derivatives can suppress H9N2-induced cytokines production through MAPKs and STAT3 
signaling pathways. These results underscore the immunomodulatory effects of indirubin derivatives on 
pulmonary endothelium and its therapeutic potential on IAV-infection.
Influenza A viruses (IAV) cause seasonal epidemics and occasional global pandemics in human populations and 
resulted in a substantial number of deaths and economic burden1. IAV are single-stranded negative-sense RNA 
viruses that belong to the family Orthomyxoviridae. Their RNA genome is comprised of eight segments which 
encode for 11 viral proteins including the surface proteins hemagglutinin (HA) and neuraminidase (NA), matrix 
proteins M1 and M2, nonstructural proteins NS1 and NS2, and polymerase proteins PB1, PB2, PA, and PB1-F22. 
The glycoproteins HA and NA play a determinative role in viral tropism as well as pathogenesis. For instance, 
seasonal H3N2 virus mainly bind onto the epithelium of the upper respiratory track, while highly pathogenic avian 
H5N1 attaches abundantly to the lower respiratory tract3.
Nevertheless, infection of the virus triggers an immediate innate immune response of the host cells in order 
to restrict the spread of the virus. The host pathogen recognition receptors (PRRs) play a vital role in recognizing 
pathogen-associated molecular patterns (PAMPs) from invading pathogens. Its activation initiates and orchestrates 
the innate immunity during an infection4. Transmembrane toll-like receptors (TLRs), such as TLR-35/76/87/108 and 
retinoic acid-inducible gene-I-like receptors (RLRs)9 can recognize influenza viral protein or viral RNA molecules. 
Recognition of IAV by the host cell activates several intracellular signaling pathways and results in the induction of 
gene expression for cytokine or chemokines10. These cytokines and chemokines are essential in cell-cell commu-
nication and recruitment of immune cells. Gene expression of cytokines is tightly regulated by a complex network 
of signaling pathway. Mitogen-activated protein kinases (MAPKs), including p38 MAPK (p38), c-Jun N-terminal 
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kinase (JNK) and extracellular signal-regulated kinase (ERK), are the most extensively studied signaling pathway 
in the context of innate immunity11. Each MAPK has a distinct role in conveying the effects of PRRs activation. 
In general, JNK activation is pro-inflammatory12, while p38 and ERK play a role in both eliciting and turning-off 
inflammatory responses13–15. Binding of cytokines on their transmembrane receptor leads to activation of down-
stream signaling pathways, signal transducer and activator of transcription (STAT) proteins are the common 
signaling molecules which function as transcription factors for cytokines production16,17.
The epithelium of the human conducting airway18,19 and lung alveolus (Type 1 or 2 pneumocytes)20 serve as the 
primary target of IAV. However, infection of IAV induces the alveolus epithelial cells to produce cytokines that can 
further activate the endothelial cells on its basolateral side21. Recent studies on highly pathogenic avian influenza 
viruses like H5N1 subtype highlighted that lung endothelium are at the center of innate immune cells recruitment 
and excessive pro-inflammatory cytokine production during severe IAV infection22–24. Clinical presentation of 
severe IAV infection is characterized by multi-organ failure and systemic inflammatory response syndrome, also 
known as a “cytokine storm”25,26. Thus, immunomodulation of lung endothelium may serve as an attractive ther-
apeutic strategy for the treatment of IAV infection27–29.
Currently, the primary means of prevention against influenza is annual vaccination. However, the availability 
of vaccine may be overwhelmed by the rapid spread of IAV30. Also, influenza targeting agents like Amantadine 
and Rimantadine (M2-ion channel inhibitors) or Oseltamivir and Zanamivir (NA inhibitors) may select for muta-
tional escape and show widespread resistance31. In addition, use of antiviral agents alone may not be enough for 
IAV-infected patients with over-activated immune responses. Modulation of the host immune response has the 
potential advantage to overcome the above problems32.
The search for novel antiviral and immunomodulatory drugs against influenza concentrates not only on syn-
thesis of new drugs, but also compounds isolated from natural sources33. Our previous study showed that ginse-
nosides derived from Panax ginseng have anti-inflammatory effects on IAV-infected endothelial cells34. Indirubin 
originates from the root of herbal plant Isatis indigotica, Strobilanthes cusia and Polygonum tinctorium, has been 
used to treat sore throat and flu in Chinese Medicine. Molecular studies have shown its potent inhibitory effects 
on various kinases, including mitogen-activated protein kinases (MAPKs)35,36 and Src kinases37. Since indirubin 
shows poor solubility and bioavailability, several derivatives have been chemically synthesized to improve its 
functional activities. It has been previously shown that indirubin and its derivatives are potent antiviral38,39 and 
anti-inflammatory40–42 compounds. Here we investigated the immunomodulatory effects of two indirubin deriva-
tives, indirubin-3′ -(2,3-dihydroxypropyl)-oximether (E804) and indirubin-3′ -oxime (E231) on influenza A virus 
(H9N2) infected-human pulmonary microvascular endothelial cells (HPMECs).
Material and Methods
Chemicals. Indirubin-3′ -oxime (E231) was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Indirubin-3′ -(2,3-dihydroxypropyl)-oximether (E804) was purchased from Calbiochem (La Jolla, CA, USA). 
The following antibodies, including anti-phospho p38 (Thr180/Tyr182), anti-p38, anti-phospho JNK (Thr183/Tyr185), 
anti-JNK, anti-phospho ERK (Thr202/Tyr204), anti-ERK, anti-STAT3, and anti-phospho STAT3 (Tyr705) were 
obtained from Cell Signaling Technology (Beverly, MA, USA). Anti-GAPDH and anti-lamin A/C were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Secondary antibody was purchased from Invitrogen 
(Carlsbad, CA, USA). Endothelial cell growth supplement (ECGS) was purchased from Millipore (Billcerica, MA, 
USA). Penicillin and streptomycin mixture (PS) and fetal bovine serum (FBS) were purchased from Invitrogen. 
Other chemicals not specified are obtained from Affymetrix USB Chemical (Cleveland, OH, USA).
Influenza A virus. Influenza A/H9N2 virus (A/Quail/HongKong/G1/97) was used in this study. Viruses were 
cultured in MDCK cells (ATCC, Manassas, VA, USA) before the infection experiments. Virus infectivity was 
assessed by plaque forming assay in MDCK cells. Isolation of influenza A virus (IAV) subtype A/Quail/Hong 
Kong/G1/97 (H9N2) was described elsewhere43.
Cell cultures and influenza A virus infection. Human pulmonary microvascular endothelial cells 
(HPMECs) were obtained from ScienCell (San Diego, CA, USA). Cells were cultured in M199 medium sup-
plemented with heparin (90 mg/L, w/v), heat-inactivated FBS (20%, v/v), ECGS (20 μ g/ml) and PS (1%, v/v) 
and kept at incubator maintained in 37 °C and 5% CO2. HPMECs were passaged and assayed within the passage 
3–11 to ensure genetic stability. Cells were seeded on gelatin (0.1%)-coated cell culture plate. After a PBS wash, 
HPMECs were inoculated with IAV using a multiplicity of infection (MOI) of 2 at 37 °C. After 1 h of infection, 
cells were washed with PBS and then treated with or without indirubin derivatives. Mock-infected cells were used 
as negative control.
Quantitative analysis of cytokines by enzyme-linked immunosorbent assays (ELISA). After 
treating with indirubin derivatives for 24 h, culture supernatant was harvested. The levels of cytokines (IP-10, 
RANTES, IL-6, IL-1β , MCP-1, TNF-α ,) were quantified by sandwich ELISA according to the manufacturer’s 
protocol (R&D Systems, Minneappolis, MN, USA).
Cell viability assays. HPMECs (1 × 104 cells/well) were seeded onto 96-well plates. After treatment with 
various concentrations of indirubin derivatives for the indicated time, cell viability was determined by MTT 
assay44. The absorbance at wavelength of 540 nm was measured by the ELx800 Absorbance Reader (BioTek, 
Winooski, VT, USA). Percentage of cell viability was determined by the following formula: Absorbance treatment 
group – Absorbance blank)/(Absorbance vehicle control group – Absorbance blank).
Real-time reverse transcription-polymerase chain reaction (RT-PCR) for mRNA quanti-
tation. After treatment, total RNA in HPMECs was extracted by TRIzol (Invitrogen) following the 
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manufacturer’s instruction. Complementary DNA was synthesized from DNase-treated total RNA using 
Superscript II first-strand synthesis system (Invitrogen). The relative expression of target gene was quantified 
by real-time RT-PCR using KAPA SYBR Fast ABI prism qPCR Kit (KAPA Biosystems, Woburn, MA, USA) 
and detected by a StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA, USA). The relative 
expression of target gene was normalized by the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
and then calculated by the comparative Ct method.
Plaque assay. The virus titers were determined by standard plaque assay on Madin-Darby canine kidney 
(MDCK) cells. In brief, MDCK cells were grown in MEM and seeded onto 6-well plates. Diluted cell culture 
medium from influenza virus-infected HPMECs were added to the confluent MDCK cells monolayers for 1h. 
Then, the inoculum was removed, and a mixture of agarose (2%, w/v) containing L-(tosylamido-2-phenyl) ethyl 
chloromethyl ketone (TPCK) (1 μ g/ml) was added onto the MDCK cells monolayers. After 72 h of incubation, 
the plate was fixed by formaldehyde (4%, v/v) overnight and then the agarose was discarded. The plaques were 
counted after staining with crystal violet (0.2%, w/v).
Subcellular fractionation and Western blot analysis. Cytoplasmic and nuclear extract 
were prepared by NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, 
Rockford, IL, USA) according to the manufacturer’s protocol. For extraction of whole-cell 
lysate,  cel ls  were lysed by CytoBusterTM Protein Extraction Reagent (Novagen, Madison, 
WI, USA) containing protease (0.5%, v/v) and phosphatase inhibitor cocktails (0.5%, v/v) 
(Calbiochem, San Diego, CA, USA). The cell lysate was collected after centrifugation. Protein concentration of 
the sample was determined by the detergent-compatible protein assay (Bio-Rad, Hercules, CA, USA). Equal 
amounts of protein were loaded and separated by 10% SDS-PAGE followed by electroblotting onto nitrocellu-
lose membrane. The membrane was soaked in blocking buffer (1% non-fat milk in TBS-T, w/v) and then incu-
bated with specific primary antibodies overnight at 4 °C and secondary antibody for 1 h at room temperature. 
Immunoreactive bands were visualized using SuperSignal West Pico Kit (Thermo Scientific).
In vitro mitogen-activated protein kinases assay. To detect the activity of individual MAPKs after 
treatment with IAV and indirubin derivatives, the non-radioactive In vitro protein kinase assay kit from Cell 
Signaling Technology was used. In brief, the Sepharose bead-immobilized antibody was used to immunopre-
cipitate active MAPKs from an equal amount of total cell lysate (200 μ g) overnight. The immunoprecipitate was 
washed twice with cell lysis buffer and kinase reaction buffer. The immunoprecipitate were then incubated with 
indirubin derivatives E804 or E231 (1 μ M) for 3 min before addition of ATP. Subsequently, kinase reactions using 
corresponding protein substrate were performed at 37 °C for 30 min. The kinase reaction was stopped with SDS 
loading buffer. Phosphorylation of protein substrate was detected by immunoblotting with specific antibody.
Immunofluorescence microscopy. HPMECs at a density 1 × 104 were seeded onto a glass coverslip in 
a 24-well plate. After treatment for the indicated time, cells were fixed with 4% paraformaldehyde for 15 min 
at room temperature. Cells were incubated with primary antibody (1: 200 dilution rabbit anti-phospho-STAT3 
(Tyr705) antibody) overnight at 4 °C. The coverslip was washed and then incubated with FITC-conjugated goat 
anti-rabbit secondary antibody (1: 250 dilution) (Invitrogen) for 2 h at room temperature. Nuclei were visualized 
by staining with DAPI (0.5 μ g/ml). The coverslip was washed and mounted on a slide using DAKO fluorescence 
mounting medium (Carpinteria, CA, USA). Fluorescence image was captured by the Olympus Fluoview FV1000 
confocal laser-scanning microscope (Tokyo, Japan).
Small interfering RNA (siRNA) transfection. Transfection of siRNA was performed using Lipofectamine 
RNAiMAX (Invitrogen). Non-targeting-siRNA (50 nM) was used in parallel with STAT3-specific siRNA (50 nM) 
(Ambion, Austin, TX, USA). Cells plated at 80% confluence were transfected in Opti-MEM medium (Gibco BRL, 
Grand Island, NY, USA) for 24 h. After transfection, cells were rinsed with Opti-MEM prior to further treatment.
Statistical analysis. All results were expressed as mean ± standard derivation (S.D.) of at least 3 independ-
ent experiments. Statistical significance between groups was determined by one-way ANOVA with Tukey’s post 
hoc test. p < 0.05 was considered to be statistically significant.
Results
Influenza A virus H9N2 is a potent inducer of cytokines production in pulmonary endothelial 
cells. Recent studies suggested that lung endothelium is the central regulator of cytokine amplification during 
influenza A virus infection, while dysregulation of cytokines production may result in systemic inflammation22. 
In this study, we found that the infection of influenza A virus subtype A/Quali/Hong Kong/G1/97 (H9N2) on 
HPMECs induced excessive production of various pro-inflammatory cytokines and chemokines, including IP-10 
(Fig. 1A), RANTES (Fig. 1B) and IL-6 (Fig. 1C) in a time-related manner. IL-6 was first induced at 8 h post-infec-
tion (h.p.i.), IP-10 and RANTES were induced after 24 h.p.i. However, H9N2 did not significantly increase IL-1β 
(Fig. 1D), MCP-1 (Fig. 1E) and TNF-α (Fig. 1F) in HPMECs. Meanwhile, H9N2-infection in HPMECs strongly 
induced IFN-β (Fig. 1H) and IFN-γ 1 mRNAs (Fig. 1I), but only transient IFN-α 1 mRNA (Fig. 1G) induction at 
8 h.p.i. Both IFN-β and IFN-γ 1 mRNAs expressions peak at 24 h.p.i.
Indirubin derivatives inhibit H9N2-induced cytokines expression in pulmonary endothelial 
cells. To examine the immunomodulatory effects of indirubin derivatives, HPMECs were infected with H9N2 
for 1 h followed by incubation with indirubin derivatives E804 or E231 for another 24 h. We have tested the cyto-
toxicities of indirubin derivatives in HPMECs prior to the ELISA. As shown in Fig. 2, no significant cytotoxicity 
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was observed at or below 10 μ M in HPMCEs. Next, indirubin derivatives were found to suppress H9N2-induced 
IP-10 (Fig. 3A), RANTES (Fig. 3B) and IL-6 (Fig. 3C) expression in a concentration-related manner. E804 sig-
nificantly inhibited cytokines expression at 1 μ M, a similar inhibitory effect was observed when a higher con-
centration of E231 (10 μ M) was used. Both indirubin derivatives slightly induced and inhibited the basal level of 
RANTES and IL-6 respectively. It may be due to the regulatory effects of indirubins on innate immunity45. For 
Figure 1. Infection of H9N2 on human pulmonary endothelial cells strongly induces expression of 
multiple cytokines. HPMECs were infected with H9N2 at 2 MOI. Cell culture supernatant or total RNA were 
harvested at the indicated time point. The levels of (A) IP-10, (B) RANTES, (C) IL-6, (D) IL-1β , (E) MCP-1, 
and (F) TNF-α were measured by ELISA. The mRNA levels of (G) IFN-α 1, (H) IFN-β and (I) IFN-γ 1 were 
quantified by real-time RT-PCR. The values are presented as mean ± S.D. from three independent experiments. 
*p < 0.05, **p < 0.01, ***p < 0.001 vs mock-infected cells.
Figure 2. The cytotoxicities of indirubin derivatives E804 and E231. HPMECs were incubated with E804 or 
E231 (0.1, 0.5, 1, 5 and 10 μ M) for 24 h. Cell viability was determined by MTT assay. The values are presented as 
mean ± S.D. from three independent experiments.
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the IFN-β (Fig. 3D) and IFN-γ 1, (Fig. 3E) both E804 and E231 (1 μ M) could significantly reduce H9N2-induced 
expression. On the other hand, to examine the antiviral property of indirubin derivatives, we measured the viral 
matrix 1 (M1) gene expression in HPMECs. The RT-PCR result showed that H9N2 could efficiently replicate and 
transcribe viral protein in HPMECs, but neither indirubin derivatives E804 nor E231 could reduce H9N2 M1 
Figure 3. Indirubin derivatives E804 and E231 suppress H9N2-induced cytokines production in HPMECs 
in a concentration-related manner. HPMECs were infected with H9N2 at 2 MOI followed by treatment with 
indirubin derivatives E804 or E231 (0.1, 1, 10 μ M) for another 24 h. Cell culture supernatant and total RNA were 
harvested and the levels of (A) IP-10, (B) RANTES and (C) IL-6 were measured by ELISA. The mRNA levels 
of (D) IFN-β and (E) IFN-γ 1 were quantified by real-time RT-PCR. The values are presented as mean ± S.D. 
from three independent experiments. **p < 0.01, ***p < 0.001 vs mock-infected cells. #p < 0.05, ##p < 0.01, 
###p < 0.001 vs H9N2-infected cells.
Figure 4. Indirubin derivatives E804 and E231 do not affect H9N2 replication in human pulmonary 
endothelial cells. HPMECs were infected with H9N2 at 2 MOI followed by treatment with indirubin derivatives 
E804 or E231 (1 μ M) for another 24 h. (A) The mRNA level of influenza M1 gene was quantified by real-time 
RT-PCR. (B) The viral titers were quantified by standard plaque formation assay in MDCK cells. The values are 
presented as mean ± S.D. from three independent experiments. ***p < 0.001 vs mock-infected cells. ND = Not 
Detected.
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gene expression (Fig. 4A). The plaque formation assay further confirmed efficient virus replication in HPMECs 
(Fig. 4B). However, both indirubin derivatives cannot reduce the virus titer in H9N2-infected HPMECs.
H9N2-induced IP-10, RANTES and IL-6 expressions are mediated through MAPKs. To inves-
tigate the signaling pathways that mediate the induction of cytokines production during H9N2 infection in 
HPMECs, cells were treated with MAPKs specific chemical inhibitors after H9N2 infection, or transfected with 
STAT3-specific siRNA before H9N2 infection. The ELISA results showed that JNK inhibitor SP600125 partially 
inhibited H9N2-induced IP-10 (Fig. 5A) and RANTES (Fig. 5B) production. Also, the p38 inhibitor SB203580 
could significantly suppress the production of IL-6 (Fig. 5C) and showed partial inhibition on IP-10 (Fig. 5A) 
expression induced by H9N2. To confirm the suppressive effects of different MAPKs inhibitors on cytokines are 
not due to impaired viral replication, we introduced viral RNA into HPMECs as a non-dynamic viral stimulus. 
HPMECs were transfected with viral RNA or cellular RNA in the presence or absence of different MAPKs inhib-
itors (Supplementary figure 1)46. Similar to the results of direct virus infection, viral RNA stimulated cytokines 
expressions, and the inhibitory effects of MAPKs inhibitors were very similar to the experiments in direct infec-
tion. This confirmed that the suppression effects of MAPKs inhibitors on cytokines expression were not due to 
their potential effects on viral load. As a result, the anti-inflammatory effects of indirubin derivatives are mainly 
due to its inhibitory effects on different kinases.
In contrast, STAT3-specific siRNA had no effects on IP-10, RANTES and IL-6 production induced by H9N2 
infection in HPMECs (Fig. 5D–F). Time-course experiments showed that H9N2 rapidly induced p38 and JNK 
phosphorylation in 15 min after addition of the virus, then a second wave of p38 and JNK phosphorylation were 
induced at 24 h.p.i. and 6 h.p.i., respectively (Fig. 6A,B). No activation of ERK was found after H9N2 infection. 
Similar to the early phosphorylation of stress-related MAPKs, STAT3 was phosphorylated early in 30 min after 
addition of the virus. However, the second wave of STAT3 phosphorylation was found at 2 h.p.i. Taken together, 
these results suggested that H9N2 infection on HPMECs could activate p38, JNK and STAT3 signaling pathways 
rapidly, and the expression of cytokines including IP-10, RANTES and IL-6 were mainly due to the activation of 
p38 and JNK.
Indirubin derivatives suppress H9N2-induced cytokines expression through direct inhibition 
of p38 and JNK activity. To study the underlying mechanism of the anti-inflammatory effects of indirubin 
derivatives, HPMECs were treated with indirubin derivatives E804 or E231 after H9N2 infection. As shown in 
Fig. 7, E804 can significantly reduce H9N2-induced phosphorylation of p38 (Fig. 7A) and JNK (Fig. 7B) at 24 and 
6 h.p.i., respectively, and E804 demonstrated a more potent effect than E231. It has been suggested that indirubin 
Figure 5. H9N2-induced IP-10, RANTES and IL-6 productions in human pulmonary endothelial cells 
are mediated through MAPKs. (A–C) HPMECs were infected with H9N2 at 2 MOI followed by treatment 
with either SP600125 (JNK inhibitors) (10 μ M), SB203580 (p38 inhibitor) (10 μ M), PD98059 (ERK inhibitor) 
(10 μ M), indirubin derivatives E804 (1 μ M) or E231 (1 μ M) for another 24 h. (D–F) HPMECs transfected with 
non-targeting siRNA (50 nM) or STAT3 specific siRNA (50 nM) were infected with H9N2 at 2 MOI for 1 h, 
and further incubated for 24 h.p.i. Cell culture supernatant was harvested and the levels of IP-10, RANTES and 
IL-6 were measured by ELISA. The values are presented as mean ± S.D. from three independent experiments. 
***p < 0.001 vs mock-infected cells. #p < 0.05, ##p < 0.01, ###p < 0.001 vs H9N2-infected cells.
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and its derivatives are potent inhibitors of various kinases, including MAPKs. In vitro kinase assay on p38 and 
JNK showed that E804 but not E231 inhibited p38 and JNK kinases activity. This action was reflected by the 
reduced phosphorylation of their direct downstream substrates ATF2 (Fig. 7C) and c-Jun (Fig. 7D) respectively.
Indirubin derivatives prevent H9N2-induced IFN-β expression through inhibition of STAT3 
phosphorylation and nuclear translocation. Though we found no relationship between STAT3 and 
H9N2-induced IP-10, RANTES and IL-6 expressions (Fig. 5D–F), STAT signaling pathway is indispensable for 
the induction of interferons. We showed that knockdown of STAT3 strongly inhibited H9N2-induced IFN-β 
Figure 6. Infection of H9N2 on human pulmonary endothelial cells induces rapid phosphorylation of p38, 
JNK, and STAT3. HPMECs were infected with H9N2 at 2 MOI. Total cell lysates were harvested at the indicated 
time (0.25, 0.5 and 1 h after addition of virus, and 0.25, 0.5, 1, 6 and 24 h.p.i.). Phosphorylation and total p38, 
JNK, ERK and STAT3 were detected by Western blot analysis with specific antibodies. (A) Representative 
image from three independent experiments. (B) Quantitative analysis of Western blotting. Values are presented 
as fold-change of phosphorylated p38, JNK, ERK or STAT3 normalized to the corresponding total form and 
then compared with mock-infected cells. The values are presented as mean ± S.D. from three independent 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs mock-infected cells.
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(Fig. 8A) but not IFN-γ 1 (Fig. 8B) mRNA expression. To elucidate the inhibitory effects of E804 on STAT3, 
Western blot analysis was performed. Treatment with E804 or E231 inhibited H9N2-induced STAT3 tyrosine 
phosphorylation (Fig. 8C). Upon activation, STAT3 forms homo- or heterodimers that translocate to the nucleus. 
HPMECs fractionation of nucleus and cytoplasm was obtained by means of subcellular fractionation followed by 
Western blot analysis. The results showed that H9N2 infection increased phosphorylated STAT3 in the nuclear 
fraction, while treatment with E804 significantly reduces the nuclear translocation (Fig. 8D). Similar to the result 
of Western blot analysis, the confocal image also showed that increased fluorescence signal was found in the 
nucleus after H9N2 infection in HPMECs (Fig. 8E). Treatment with E804 reduced STAT3 fluorescence signal in 
the nucleus.
Discussion
The emergence of IAV poses a serious global threat to human health. Besides regular epidemic outbreaks, severe 
pandemics like the 1918 Spanish flu and the more recent 2009 swine flu had caused enormous social and economic 
burden. Current treatment of IAV infection by M2-ion channel inhibitors or NA inhibitors emerged high frequency 
of resistance, and the efficacy and effectiveness of these antiviral drugs are limited by disappointing success rate1, 
so alternative or complementary therapies that modulate the signaling pathways utilized by IAV came into focus. 
In this report, we demonstrated that indirubin derivatives, particularly E804 is a potent immunomodulatory 
compound for IAV-infection in vitro by inhibiting intracellular signaling pathways in pulmonary endothelial cells.
During the early stage of IAV infection, innate immune cells are recruited to the site of infection and are 
associated with an overwhelming production of pro-inflammatory cytokines and chemokines. Endothelial cells 
in the pulmonary vasculature form a barrier between the blood and interstitium. This strategic position suggests 
that pulmonary endothelial cells are prone to be affected by the cytokines and viral particles released from the 
IAV-infected epithelial cells. A recent study by Teijaro et al. identified endothelial cells as the central orchestra-
tor which contribute to the aberrant pro-inflammatory cytokine and chemokine production during early IAV 
infections22. Concomitant with our in vitro data, we showed that H9N2 virus can efficiently infect HPMECs 
(Fig. 4A,B) and induce a significant amount of IP-10, RANTEs, IL-6, IFN-β and IFN-γ 1. IP-10 and RANTES are 
Figure 7. Indirubin derivatives E804 and E231 inhibit H9N2-induced p38 and JNK signaling pathways 
in human pulmonary endothelial cells. (A,B) HPMECs were infected with H9N2 at 2 MOI followed by 
treatment with indirubin derivatives E804 or E231 (1 μ M). Total cell lysates were harvested at 24 h.p.i. (for 
p-p38) or 6 h.p.i. (for p-JNK). Phosphorylation and total p38 and JNK were detected by Western blot analysis 
with specific antibodies. Representative image from three independent experiments (Upper panel). Quantitative 
analysis of Western blotting. Values are presented as fold-change of phosphorylated p38 or JNK normalized 
to corresponding total form, and then compared with mock-infected cells (Lower panel). (C,D) E804 directly 
inhibits p38 and JNK kinases activity in vitro. HPMECs were infected with H9N2 at 2 MOI. Cell lysates 
were harvested at 24 h.p.i. (for p-p38) or 6 h.p.i. (for p-JNK). In vitro kinase assay of p38 and JNK was then 
performed as described in materials and methods. Representative image from three independent experiments 
(Upper panel). Quantitative analysis of Western blotting. Values are presented as fold-change of phosphorylated 
ATF2 or c-Jun compared with mock-infected cells (Lower panel). The values are presented as mean ± S.D. of 
three independent experiments. **p < 0.01, ***p < 0.001 vs mock-infected cells, #p < 0.05 vs H9N2-infected 
cells.
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the chemoattractants for leukocytes including T cells, NK cells, and granulocytes, while production of IL-6 by 
endothelial cells initiates infiltration of neutrophils in the early phase of infection47. These cytokines have been 
found histopathologically in the lungs (including epithelial and endothelial cells) of H5N1 infected patients, who 
showed acute respiratory distress syndrome (ARDS)48, and ARDS can be characterized by progressive pulmonary 
endothelial damage. It has been suggested that treatment with antibodies against IP-10 in H1N1 infected mice 
can improve the survival rate and reduce acute lung injury49. Furthermore, suppression of early innate cytokine 
and chemokine production in the pulmonary endothelium can significantly improve survival of mice infected 
with lethal H1N1 Swine IAV22. These studies suggested that inhibition of cytokines production of the pulmonary 
endothelium is an attractive therapeutic strategy against IAV-induced cytokine storm.
Since severe infection of the influenza virus triggers the activation of the innate immune response and sometimes 
results in the induction to a cytokine storm. In this study, we demonstrated the immunomodulatory effects of indi-
rubin derivatives, particularly E804 on IAV-infected pulmonary endothelial cells. Over the past two decades, many 
studies have identified that indirubin derivatives are potent inhibitors of various kinases, including MAPKs35,36, 
Src kinase37, glycogen synthase kinase-3β (GSK-3β )50 and cyclin-dependent kinases (CDKs)51. Based on these 
findings, potential functions of indirubin derivatives have been proposed, including anti-inflammation35,40–42, 
anti-leukemia36, antiviral38,39 and angiosuppression52,53. Crystal structure analysis revealed that indirubin can form 
three hydrogen bonds with the ATP-binding pocket of CDKs, thereby competitively inhibiting ATP binding in 
the catalytic domain of CDKs36. The results from our in vitro kinase assay also demonstrated that E804 is a potent 
inhibitor of p38 and JNK (Fig. 7C,D). The cytokine ELISA data also suggest that H9N2-induced IP-10 expression 
of HPMECs was dependent on p38 and JNK activation, while RANTES and IL-6 were controlled by JNK and p38, 
respectively (Fig. 5A–C). However, the Western blot analysis showed that E804 could also inhibit phosphorylation 
Figure 8. Indirubin derivatives suppress H9N2-induced IFN-β mRNA expression through inhibiting 
STAT3 signaling pathway. (A,B) HPMECs transfected with non-targeting siRNA (50 nM) or STAT3 specific 
siRNA (50 nM) were infected with H9N2 at 2 MOI for 1 h, and further incubated for 24 h.p.i. The mRNA levels 
of IFN-β and IFN-γ 1 were quantified by real-time RT-PCR. (C) HPMECs were infected with H9N2 at 2 MOI 
followed by treatment with indirubin derivatives E804 or E231 (1 μ M). Total cell lysates were harvested at  
2 h.p.i. Phosphorylation and total STAT3 were detected by Western blot analysis with specific antibodies.  
(D) Subcellular fractionation was performed 2 h post infection. Western blot analysis was performed to 
determine the translocation of STAT3 from cytoplasm to nucleus. The GAPDH and Lamin A/C denoting the 
cytoplasmic and nuclear fractions respectively. Representative images from three independent experiments 
(Upper panel). Band intensities were determined by quantitative densitometry. Values are presented as fold-
change of phosphorylated STAT3 normalized to total STAT3, and then compared with mock-infected cells 
(Lower panel). The values are presented as mean ± S.D. from three independent experiments. ***p < 0.001 vs 
mock-infected cells, ###p < 0.001 vs H9N2-infected cells. (E) Immunofluorescent staining of HPMECs with anti-
phosphorylated STAT3 (Y705) antibody (Green). DAPI staining (Blue) was used to show the nucleus.
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of p38 (Fig. 7A) and JNK (Fig. 7B), which mean upstream kinases of p38 and JNK may also be inhibited by E804. 
MAPKs are important mediators of influenza-induced cytokine expression. In fact, p38 has been shown to regulate 
the stability of IL-6 mRNA54. Meanwhile, another study also indicated the critical function of p38 on IP-10 during 
viral infection55. Furthermore, inhibition of p38 by specific inhibitor SB202190 in vivo can greatly diminish H5N1 
lethal infection28. However, the role of JNK in IAV infection has not been fully examined. Nacken et al. elucidated 
that influenza viral RNA induces JNK phosphorylation in an RIG-I dependent manner, but the NS1 of IAV has 
also an intrinsic JNK activating property56. Taken together, the potent inhibitory effect of p38 and JNK signaling 
pathways by E804 strongly correlates with its anti-inflammatory function.
IFNs are pro-inflammatory cytokines crucial for antiviral responses to IAV infection. STAT1 and STAT2 are 
predominant and essential transcription factors of type I and II interferons signaling pathway, but the role of 
STAT3 activation after IFN binding remains controversial. Undeniably, STAT3 is indispensable for downstream 
signaling pathway of many other cytokines like IL-6, VEGF or EGF57. Our data showed that H9N2 infection on 
HPMECs can significantly induce IFN-β and IFN-γ 1 expression. Interestingly, STAT3-specific siRNA has no effect 
on H9N2-induced IL-6 (Fig. 5F) and IFN-γ 1 (Fig. 8B), but strongly inhibit IFN-β expression level, indicating the 
involvement of STAT3 in IFN-β induction. The Western blot data showed that IAV-infection could activate STAT3 
in early stage (15 min after addition of virus) followed by another activation at 2 h.p.i. (Fig. 6). H9N2 was found to 
upregulate TLR-8 and MyD88, which is critical to the induction of IFN-β 58. In line with this finding, the early acti-
vation of STAT3 may function together with the downstream signaling molecules of TLR-8, possibly the interferon 
regulatory factors (IRFs), to induce rapid expression of IFN-β mRNA at 2 h.p.i. (Fig. 1H). And then the autocrine 
effect of IFN-β induces a further amplification of IFN-β expression and result in a cytokine storm. A previous 
study suggested that E804 could inhibit STAT3 dimerization and subsequent DNA binding37. Our translocation 
experiments clearly indicated that E804 could inhibit STAT3 phosphorylation and nuclear translocation. Since the 
induction of many pro-inflammatory cytokines requires type I interferon signaling, inhibition of IFN-β production 
by E804 may blunt the early induction of these cytokines. Though IFN-β is a well-known antiviral cytokine, it is also 
involved in the pathogenesis of influenza infection. In vivo studies focusing on the S1P1 receptor and p38 pathway 
also suggested that, even the IAV-induced IFNs were suppressed by an S1P1 receptor agonist22 or p38 inhibitor28, 
the survival rate of the infected mice could still be significantly improved if those strongly induced cytokines were 
suppressed. In many studies, increased viral load were concomitant of reduced interferons expressions. However, in 
the present study, viral titer did not further increased in indirubin derivatives treated cells (Fig. 4B) even IFNβ and 
IFN-γ 1 were suppressed, the results indicated that suppression of cytokines produced by the infected pulmonary 
endothelium could reduce IAV pathogenicity independent of the viral clearance. In fact, many kinases including 
CDK39 and MAPKs, which are suggested being involved in the influenza replication process are also the target of 
indirubin derivatives, this might explain the partial antiviral effect of indirubin derivatives in this model.
Figure 9. The schematic figure of immunomodulatory effects of indirubin derivatives against H9N2-
infected HPMCEs. Infection of H9N2 on HPMECs induced rapid phosphorylation of p38, JNK and STAT3. 
H9N2-induced expression of IP-10, RANTEs and IL-6 were mediated through JNK and p38 signaling pathways. 
Meanwhile the phosphorylation and nuclear translocation of STAT3 leaded to induction of IFN-β . Indirubin 
derivatives particularly E804 is a potent inhibitor of p38 and JNK signaling pathways. E804 could also reduce 
the phosphorylation and nuclear translocation of STAT3. By inhibition of these signaling pathways, E804 could 
significantly suppress H9N2-induced cytokine burst in HPMECs.
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Conclusions
Combination therapies coupling with antiviral and immunomodulatory drugs have been investigated intensively29. 
The encouraging results from in vitro and pre-clinical studies have led to an increased interest on this topic. 
However, to achieve the best clinical outcome, antiviral and immunomodulatory drugs should be administrated at 
the appropriate time during an infection. Further understanding of the immune dynamic could allow us to design 
an optimum therapy strategy. In this report, we demonstrated for the first time, the potent immunomodulatory 
effects of indirubin derivatives on pulmonary endothelial cells and their therapeutic potential for IAV-infection 
(Fig. 9). As a result, the combinational effects of indirubin derivatives and antiviral drug in animal model warrant 
further investigation.
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